KH 631
Alternative Names: KH-631Latest Information Update: 31 Aug 2023
At a glance
- Originator Chengdu Kanghong Pharmaceutical
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
Most Recent Events
- 31 Aug 2023 Phase-I clinical trials in Wet age-related macular degeneration (Treatment-experienced) in USA (Intraocular, Injection) (NCT05657301)
- 06 Feb 2023 Phase-I/II clinical trials in Wet age-related macular degeneration (Treatment-experienced, In adults, In the elderly) in China (Intraocular) (NCT05672121)
- 05 Jan 2023 Chengdu Origen Biotechnology plans a phase I/II trial in Wet age-related macular degeneration in China (Intraocular, Injection) (NCT05672121)